Kenny Walter

While 20% of the patient population had a Fib-4 index greater than 1.3, including 1 case of a Fib-4 index greater than 2.67, the investigators did not identify a significant increase in Fib-4 index in patients with fatty liver compared to those who did not develop fatty liver.

Older age and use of various medications, including antibiotics, proton pump inhibitors, and corticosteroids were associated with a higher risk of developing C difficile infections.

The rate of adverse events was lower in the combination group than it was in patients in the guselkumab or golimumab monotherapy groups at week 50.

The same risk was not found for offspring of fathers with primary immunodeficiencies.

The majority of healthcare workers included in the study were immune to both measles and rubella.

Announced on February 1, the US Food and Drug Administration's approval of daprodustat (Jesduvroq) represents their first approval of an oral agent for the treatment of anemia caused by chronic kidney disease in people on dialysis.

The FDA has approved several biologics in recent years for the treatment of patients with inflammatory bowel disease.

There is very little data on long-term outcomes from pediatric patients with inflammatory bowel disease treated with anti-TNF biosimilars.

Adalimumab-atto will be used to treat several inflammatory diseases, including rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis.

Risankizumab is the latest biologic approved by the FDA and the first-ever IL-23A targeted therapy approved for the treatment of patients with Crohn's disease.

The FDA has set a PDUFA date for daprodustat for February 1 for adult patients with chronic kidney disease.

Crosbie presented results from a small pilot study testing a video game platform for patients with executive function deficits during the annual APSARD meeting.

The 2 strains identified were highly similar and exhibited differences of only 2 single-nucleotide polymorphisms.

SARS-CoV-2 infections cause microbiome dysbiosis in patient and possibly an increase in opportunistic pathogens and a decrease in beneficial bacteria.

The new polymerase chain reaction method was evaluated for specificity, sensitivity, and repeatability using 69 C difficile isolates and 74 fecal samples.

MDR colonization was associated with MDR infection and colonization and infection was linked to higher numbers and duration of antibiotic use.

The company announced they will no longer pursue approval for the treatment despite positive data from recent phase 2 trials.

The use of cannabis was associated with more severe levels of pain, as well as more severe disease activity.

General practitioners and rheumatologists were viewed as sources of information that led to positive views toward vaccinations, while internet chatrooms, social media, and mainstream media were seen as sources of information that led to negative views.

Patients with COVID-19 and CDI had a higher incidence of sepsis, shock, ICU admission, and acute kidney injuries.

Individuals with level 3 care needs, participants with hypertension or stroke and residents who used canes were at a higher risk of developing norovirus-related diarrhea.

Hospital lengths of stay, costs, and readmissions were all reduced after implementing an antimicrobial stewardship program.

Falloon said IBD-associated peripheral arthritis is common, but not well understood.

There is not much data available on the interaction between Paxlovid and tacrolimus.

Dose de-escalation of tofacitinib resulted in less hospitalizations for patients with ulcerative colitis.

The potential for personalized medicine in inflammatory bowel disease might. be realized in the next few years.

Upadacitinib was not approved by the FDA until 2022 for patients with ulcerative colitis.

The 12-24 session counseling program also resulted in improvements in sleep quality, fatigue level, and stress levels for patients with inflammatory bowel disease.

The majority of patients who achieved persistence at the 12 month mark were also corticosteroid free.

The product is a combination of herbal compounds curcumin and QingDai called CurQD.